Edition:
United States

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

73.90EUR
17 Aug 2018
Change (% chg)

€-1.00 (-1.34%)
Prev Close
€74.90
Open
€74.20
Day's High
€74.60
Day's Low
€72.80
Volume
27,032
Avg. Vol
48,874
52-wk High
€88.60
52-wk Low
€16.75

Latest Key Developments (Source: Significant Developments)

Argenx ‍Announces Expansion Of Its Pipeline
Thursday, 22 Mar 2018 02:29am EDT 

March 22 (Reuters) - ARGENX NV ::‍ANNOUNCES EXPANSION OF ITS PIPELINE WITH ADDITION OF COMPLEMENT-TARGETED ARGX-117 FOR TREATMENT OF SEVERE AUTOIMMUNE DISEASES​.  Full Article

Argenx Reports Fourth Quarter Business Update And Full Year 2017 Financial Results
Thursday, 1 Mar 2018 01:00am EST 

March 1 (Reuters) - Argenx Nv ::ARGENX REPORTS FOURTH QUARTER BUSINESS UPDATE AND FULL YEAR 2017 FINANCIAL RESULTS.  Full Article

Argenx FY Total Operating Income Rises To 41.3 Million Euros
Thursday, 1 Mar 2018 01:00am EST 

March 1 (Reuters) - Argenx Nv ::FY REVENUE EUR 36.4‍​ MILLION VERSUS EUR 14.7 MILLION YEAR AGO.FY TOTAL OPERATING INCOME EUR 41.3 MILLION VERSUS EUR 17.2 MILLION YEAR AGO.FY TOTAL COMPREHENSIVE LOSS EUR ‍​28.1 MILLION VERSUS LOSS OF EUR 21.4 MILLION YEAR AGO.CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS EUR 359.8 MILLION AT DEC. 31.IN 2018 PLANS TO REPORT FULL DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN GENERALIZED MG.FY OPERATING LOSS EUR 22.9 MILLION VERSUS LOSS EUR 21.4 MILLION YEAR AGO.IN 2018 PLANS TO REPORT TOPLINE DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN ITP.IN H2 PLANS TO REPORT INTERIM DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN PEMPHIGUS VULGARIS.BEFORE END-2018 PLANS TO PROGRESS ARGX-113 INTO PHASE 3 CLINICAL DEVELOPMENT IN GENERALIZED MG.IN Q2 PLANS TO REPORT FULL DATA OF PHASE 1 HEALTHY VOLUNTEER TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113.IN H2 PLANS TO PROVIDE AN UPDATE ON PHASE 1/2 CLINICAL TRIAL IN AML.BY END-YEAR PLANS TO REPORT FULL DATA OF AML PHASE 1/2 AND CTCL PHASE 2 CLINICAL TRIALS OF ARGX-110.BEFORE END-2018 PLANS TO LAUNCH PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-110 IN AML.BEFORE END-2018 PLANS TO REPORT FULL DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN ITP.  Full Article

Argenx Announces Closing Of U.S. Public Offering For Gross Proceeds Of About $266 Mln
Monday, 18 Dec 2017 04:01pm EST 

Dec 18 (Reuters) - Argenx Nv ::REG-ARGENX ANNOUNCES CLOSING OF U.S. PUBLIC OFFERING FOR GROSS PROCEEDS OF APPROXIMATELY $266 MILLION.‍EACH OF ADSS OFFERED REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE​.‍CLOSING OF ITS PUBLIC OFFERING IN UNITED STATES OF 5,106,000 AMERICAN DEPOSITARY SHARES AT PRICE OF $52.00 PER ADS​.  Full Article

Argenx Raises About $231 Mln In Gross Proceeds In Upsized U.S. Offering
Wednesday, 13 Dec 2017 07:27pm EST 

Dec 14 (Reuters) - Argenx Nv ::ARGENX RAISES APPROXIMATELY $231 MILLION IN GROSS PROCEEDS IN AN UPSIZED U.S. PUBLIC OFFERING.‍ARGENX HAS GRANTED UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 666,000 ADSS​.‍PRICING OF ITS PUBLIC OFFERING IN UNITED STATES WITH ANTICIPATED GROSS PROCEEDS ABOUT $231 MILLION FROM SALE OF 4,440,000 ADSS, AT $52/ADS​.  Full Article

Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS
Wednesday, 13 Dec 2017 06:00am EST 

Dec 13 (Reuters) - Argenx Nv ::HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS.NOMINAL VALUE OF EUR 0.10 PER SHARE.ALL OF ADSS IN PROPOSED OFFERING ARE TO BE SOLD BY ARGENX..  Full Article

Argenx Files For Offering Of Up To $150 Mln American Depositary Shares
Monday, 11 Dec 2017 04:19pm EST 

Dec 11 (Reuters) - Argenx Nv ::ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING.  Full Article

Argenx announces launch of proposed public offering in United States
Monday, 11 Dec 2017 04:10pm EST 

Dec 11 (Reuters) - Argenx Nv ::ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES.ARGENX NV - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF AMERICAN DEPOSITARY SHARES.ARGENX NV - EACH OF ADSS OFFERED IN OFFERING REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.  Full Article

Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110
Monday, 11 Dec 2017 01:05am EST 

Dec 11 (Reuters) - ARGENX NV ::TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.  Full Article

Argenx Reports Positive Topline Results From Phase 2 Trial Of ARGX-113
Monday, 11 Dec 2017 01:00am EST 

Dec 11 (Reuters) - Argenx Nv ::REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF ARGX-113.FAVORABLE TOLERABILITY PROFILE CONSISTENT WITH PHASE 1 DATA.ARGX-113 TREATMENT RESULTED IN A STRONG CLINICAL IMPROVEMENT OVER PLACEBO DURING ENTIRE DURATION OF STUDY.75% OF ARGX-113 TREATED PATIENTS HAD SIGNIFICANT IMPROVEMENT IN 6 WEEKS VERSUS 25% OF PATIENTS ON PLACEBO.TOPLINE DATA FOR ITP TRIAL EXPECTED IN H2 2018.INTERIM DATA FROM PV TRIAL EXPECTED IN H2 2018.ARGX-113 (EFGARTIGIMOD) IS USED IN GENERALIZED MYASTHENIA GRAVIS.  Full Article

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS